Mallinckrodt

Mallinckrodt

Specialty pharmaceutical developer, manufacturer, distributor

Overview

Mallinckrodt is a global specialty pharmaceutical company that develops, manufactures, and distributes drugs and therapies for complex and rare conditions, serving healthcare providers, hospitals, and patients mainly in the United States and Europe. Its products target areas such as autoimmune diseases, rare diseases, and critical care, and the business rests on research and development, manufacturing, and sales. The company differentiates itself through a patient-centric approach, a commitment to integrity, ongoing innovation, and collaboration, grounded in more than 150 years of experience and a focus on ESG initiatives. Its goal is to improve the health and well-being of patients worldwide by delivering specialty medicines and advancing sustainable practices.

About Mallinckrodt

Simplify's Rating
Why Mallinckrodt is rated
C
Rated C on Competitive Edge
Rated B on Growth Potential
Rated D+ on Differentiation

Industries

Industrial & Manufacturing

Biotechnology

Healthcare

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Hazelwood, Missouri

Founded

1867

Get referred to Mallinckrodt

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • May 12, 2026 guidance reaffirmed $1.94 billion to $2.00 billion sales.
  • First-quarter 2026 sales reached $468 million, up $261 million year over year.
  • Keenova booked $23 million merger synergies and targets $150 million annual run-rate savings.

What critics are saying

  • Opioid litigation still shadows the business after 2023 and 2025 bankruptcies.
  • Integration failure or synergy misses would damage 2026 EBITDA guidance and NYSE listing plans.
  • Another leverage shock or adverse court ruling could force a third restructuring.

What makes Mallinckrodt unique

  • Acthar Gel and XIAFLEX anchor Keenova's branded specialty franchise in 2026.
  • July 31, 2025 Endo merger created a larger U.S.-focused therapeutics platform.
  • Christiana Stamoulis joined September 22, 2025 to drive M&A and corporate development.

Help us improve and share your feedback! Did you find this helpful?

Funding

Total Funding

$6.7B

Above

Industry Average

Funded Over

1 Rounds

Acquisition funding comparison data is currently unavailable. We're working to provide this information soon!
Acquisition Funding Comparison
Coming Soon

Benefits

Performance Bonus

Relocation Assistance

Stock Price

Growth & Insights and Company News

Headcount

6 month growth

-5%

1 year growth

-5%

2 year growth

-5%
PR Newswire
Nov 10th, 2025
Par Health Completes Spin-Off from Mallinckrodt, Creating an Independent Leader in Generic Pharmaceuticals and Sterile Injectables

Launches as Top 15 U.S. Generic Drug Manufacturer, Largest U.S. Producer of Active Pharmaceutical Ingredients and Premier U.S. Producer of Sterile Injectables...

Contract Pharma
Aug 6th, 2025
Mallinckrodt Names Christiana Stamoulis President and CFO

Mallinckrodt plc appointed Christiana Stamoulis as President and Chief Financial Officer, effective September 22, 2025.

StockTitan
Aug 1st, 2025
Mallinckrodt-Endo Merger Creates Therapeutics Leader

Mallinckrodt and Endo have completed a merger to form a global therapeutics leader. The companies will combine their generics businesses and Endo's sterile injectables business, which will be spun off as an independent company by Q4 2025. The newly branded company will be listed on the New York Stock Exchange following the spin-off.

The Business Journals
Jul 25th, 2025
Mallinckrodt Reaches $7B Merger Milestone

Mallinckrodt has reached a milestone in a $7 billion merger deal.

Sharecast
Mar 13th, 2025
Mallinckrodt and Endo to merge in $6.7bn deal

Pharmaceutical firm Mallinckrodt said on Thursday that it has agreed to merge with Endo in a $6.7bn deal.

Recently Posted Jobs

Sign up to get curated job recommendations

Mallinckrodt is Hiring for 66 Jobs on Simplify!

Find jobs on Simplify and start your career today

Don't see your dream role? Check out thousands of other roles on Simplify. Browse all jobs →